{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-26-000037","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.890962+00:00","generated_at":"2026-05-15T09:33:31.329907+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes","bullets":["Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.","Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.","Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.","KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.","All other directors elected with over 90% support from votes cast (excluding broker non-votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-26-000037","json":"https://secwatch.observer/filing/0000879407-26-000037.json","markdown":"https://secwatch.observer/filing/0000879407-26-000037.md","text":"https://secwatch.observer/filing/0000879407-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/0000879407-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/arwr-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:33:31.329907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}